Blink Device Company Announces TwitchView™ Quantitative Monitor for Neuromuscular Blockade is Now Compatible with Major Electronic Medical Records
Seattle, WA, June 04, 2019 --(PR.com)-- Blink Device Company announced today that the TwitchView™ quantitative train-of-four (TOF) monitor now integrates with most major electronic medical records (EMR). Commercially available in the United States, Europe, and South Korea, the TwitchView™ neuromuscular TOF monitor uses electromyography (EMG) to provide clinicians with reliable and accurate quantitative TOF data.
Justin Hulvershorn, MD, PhD, Blink’s CEO said, “Neuromuscular blocking drugs are used in almost 50% of surgeries. The literature show that, in the absence of quantitative monitoring, nearly 4 out of every 10 patients will wake up from these surgeries with significant residual paralysis, which delays recovery and can lead to life-threatening complications. To help prevent these complications, quantitative neuromuscular monitoring is rapidly becoming the standard of care when neuromuscular blocking agents are administered. Hospitals need these new monitors to integrate into the EMR to achieve significant and lasting changes in practice. Based on our recent installations and understanding of the market, we believe that the TwitchView System can be readily integrated into the EMR at over 90% of US hospitals.”
Elise Hyman, Blink’s VP of Clinical Operations added, "We are partnering with large institutions to implement hospital-wide programs to improve their management of neuromuscular blockade. These programs involve education, reliable quantitative monitoring provided by our TwitchView System, and EMR connectivity to track progress and support quality initiatives. Our mission is to provide technology that improves patient safety, and we are dedicated to working alongside clinicians and hospitals to eliminate residual paralysis."
About Blink Device Company
Blink Device Company aims to identify areas in medicine that can greatly benefit from technological innovation. Its first product is the TwitchView Quantitative Monitor for neuromuscular blockade. The company is headquartered in Seattle, Washington and their products are made in the USA. To learn more, visit www.blinkdc.com
Justin Hulvershorn, MD, PhD, Blink’s CEO said, “Neuromuscular blocking drugs are used in almost 50% of surgeries. The literature show that, in the absence of quantitative monitoring, nearly 4 out of every 10 patients will wake up from these surgeries with significant residual paralysis, which delays recovery and can lead to life-threatening complications. To help prevent these complications, quantitative neuromuscular monitoring is rapidly becoming the standard of care when neuromuscular blocking agents are administered. Hospitals need these new monitors to integrate into the EMR to achieve significant and lasting changes in practice. Based on our recent installations and understanding of the market, we believe that the TwitchView System can be readily integrated into the EMR at over 90% of US hospitals.”
Elise Hyman, Blink’s VP of Clinical Operations added, "We are partnering with large institutions to implement hospital-wide programs to improve their management of neuromuscular blockade. These programs involve education, reliable quantitative monitoring provided by our TwitchView System, and EMR connectivity to track progress and support quality initiatives. Our mission is to provide technology that improves patient safety, and we are dedicated to working alongside clinicians and hospitals to eliminate residual paralysis."
About Blink Device Company
Blink Device Company aims to identify areas in medicine that can greatly benefit from technological innovation. Its first product is the TwitchView Quantitative Monitor for neuromuscular blockade. The company is headquartered in Seattle, Washington and their products are made in the USA. To learn more, visit www.blinkdc.com
Contact
Blink Device Company
Karl Schmidt
206-708-6043
www.blinkdc.com
Karl Schmidt
206-708-6043
www.blinkdc.com
Contact
Categories